The prognostic significance of IDH mutations in AML is currently unclear. IDH2 inhibitor had been successful in the management of IDH2 positive AML patients while IDH1 inhibitor is showing promising results in ongoing clinical trials (4,20,34,40). Here, IDH1 is linked to acute myeloid leukemia.